Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 895-899

  Gutierrez Cosio S ^a   de la Rica, L ^b   Ballestar, E ^b   Santamaria C ^a   Sanchez Abarca L I ^a,c   Caballero Velazquez, T ^a,c   Blanco, B ^a   Calderon C ^c   Herrero Sanchez C ^a   Carrancio, S ^a   Ciudad, L ^b   Canizo C ^a   Miguel, J F San ^a   Perez Simon J A ^a,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

5 Azacytidine (5 aza); Epigenetic regulation; Myeloid leukemia; Preferentially expressed antigen of melanoma (PRAME); Tumor associated antigen (TAA)

Indexed keywords

AZACITIDINE; MELANOMA ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPIGENETICS; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RNA EXTRACTION;

ANTIGENS, CD34; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD DONORS; BONE MARROW CELLS; CELLS, CULTURED; CPG ISLANDS; CYTOGENETIC ANALYSIS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HEALTH; HUMANS; LEUKEMIA, MYELOID, ACUTE; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862338918     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.030     Document Type: Article

References (21)

1. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-208.
2. Epping M.T., Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006, 66:10639-10642.
3. van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998, 102:1376-1379.
4. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005, 79:257-261.
5. Santamaria C., Chillon M.C., Garcia-Sanz R., Balanzategui A., Sarasquete M.E., Alcoceba M., et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 2008, 93:1797-1805.
6. Steinbach D., Schramm A., Eggert A., Onda M., Dawczynski K., Rump A., et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006, 12:2434-2441.
7. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006, 108:4109-4117.
8. Santamaria C.M., Chillon M.C., Garcia-Sanz R., Perez C., Caballero M.D., Ramos F., et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009, 114:148-152.
9. Griffioen M., Kessler J.H., Borghi M., van Soest R.A., van der Minne C.E., Nouta J., et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res 2006, 12:3130-3136.
10. Rezvani K., Yong A.S., Tawab A., Jafarpour B., Eniafe R., Mielke S., et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113:2245-2255.
11. Steinbach D., Hermann J., Viehmann S., Zintl F., Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002, 133:118-123.
12. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
13. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., Jose-Eneriz E.S., et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 2007, 31:1521-1528.
14. Ortmann C.A., Eisele L., Nuckel H., Klein-Hitpass L., Fuhrer A., Duhrsen U., et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 2008, 87:809-818.
15. Schenk T., Stengel S., Goellner S., Steinbach D., Saluz H.P. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 2007, 46:796-804.
16. Sanchez-Abarca L.I., Gutierrez-Cosio S., Santamaria C., Caballero-Velazquez T., Blanco B., Herrero-Sanchez C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
17. Sigalotti L., Fratta E., Coral S., Tanzarella S., Danielli R., Colizzi F., et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004, 64:9167-9171.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2--Delta Delta C(T)) method. Methods 2001, 25:402-408.
19. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
20. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000, 28:1413-1422.
21. Gerber J.M., Smith B.D., Ngwang B., et al. A clinically relevant population of leukemic CD34+CD38- cells in AML. Blood 2012, [Epub ahead of print].